Curis Inc (CRIS) - Total Assets
Based on the latest financial reports, Curis Inc (CRIS) holds total assets worth $27.64 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See CRIS net asset value for net asset value and shareholders' equity analysis.
Curis Inc - Total Assets Trend (1999–2024)
This chart illustrates how Curis Inc's total assets have evolved over time, based on quarterly financial data.
Curis Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Curis Inc's total assets of $27.64 Million consist of 63.9% current assets and 36.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 48.5% |
| Accounts Receivable | $3.35 Million | 8.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $8.98 Million | 21.8% |
Asset Composition Trend (1999–2024)
This chart illustrates how Curis Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CRIS stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Curis Inc's current assets represent 63.9% of total assets in 2024, a decrease from 74.7% in 1999.
- Cash Position: Cash and equivalents constituted 48.5% of total assets in 2024, up from 9.5% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 21.0% of total assets, an increase from 0.0% in 1999.
- Asset Diversification: The largest asset category is goodwill at 21.8% of total assets.
Curis Inc Competitors by Total Assets
Key competitors of Curis Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Curis Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.70 | 1.22 | 17.14 |
| Quick Ratio | 0.70 | 1.22 | 17.18 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-6.00 Million | $4.90 Million | $162.67 Million |
Curis Inc - Advanced Valuation Insights
This section examines the relationship between Curis Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.32 |
| Latest Market Cap to Assets Ratio | 0.20 |
| Asset Growth Rate (YoY) | -46.6% |
| Total Assets | $41.27 Million |
| Market Capitalization | $8.10 Million USD |
Valuation Analysis
Below Book Valuation: The market values Curis Inc's assets below their book value (0.20x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Curis Inc's assets decreased by 46.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Curis Inc (1999–2024)
The table below shows the annual total assets of Curis Inc from 1999 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $41.27 Million | -46.60% |
| 2023-12-31 | $77.28 Million | -29.00% |
| 2022-12-31 | $108.85 Million | -32.93% |
| 2021-12-31 | $162.30 Million | -20.58% |
| 2020-12-31 | $204.36 Million | +482.10% |
| 2019-12-31 | $35.11 Million | -6.04% |
| 2018-12-31 | $37.37 Million | -49.37% |
| 2017-12-31 | $73.80 Million | +27.78% |
| 2016-12-31 | $57.75 Million | -39.19% |
| 2015-12-31 | $94.97 Million | +51.67% |
| 2014-12-31 | $62.61 Million | -22.31% |
| 2013-12-31 | $80.59 Million | +15.16% |
| 2012-12-31 | $69.98 Million | +45.25% |
| 2011-12-31 | $48.18 Million | -4.87% |
| 2010-12-31 | $50.65 Million | +40.31% |
| 2009-12-31 | $36.10 Million | -9.71% |
| 2008-12-31 | $39.98 Million | -25.71% |
| 2007-12-31 | $53.82 Million | +2.96% |
| 2006-12-31 | $52.27 Million | -14.19% |
| 2005-12-31 | $60.91 Million | -9.94% |
| 2004-12-31 | $67.63 Million | +21.35% |
| 2003-12-31 | $55.74 Million | -10.74% |
| 2002-12-31 | $62.44 Million | -56.86% |
| 2001-12-31 | $144.76 Million | -20.76% |
| 2000-12-31 | $182.68 Million | +532.29% |
| 1999-12-31 | $28.89 Million | -- |
About Curis Inc
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodyspla… Read more